A PSA decline of at least 50% to assess efficacy of treatment, as recommend by the Prostate Cancer Working Group 3, proved the single most important factor predicting PFS and OS after 225Ac-PSMA-617 treatment in our patient cohort. Here, FOLH1 is linked to prostate carcinoma.